Education
About Us
Working with TipRanks
Follow Us
Avecho Biotechnology Limited (AU:AVE)
:AVE
AVE Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
Volume188.16K
Average Volume (3M)18.89M
Market Cap
AU$12.68M
Enterprise ValueAU$4.81M
Total Cash (Recent Filing)AU$2.11M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,169,297,000
10 Day Avg. Volume14,099,416
30 Day Avg. Volume18,885,805
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Avecho Biotechnology Limited News
PremiumCompany Announcements
Avecho Secures $3M Deal with Sandoz for CBD Insomnia Capsule in Australia
PremiumCompany Announcements
Avecho Biotechnology Requests Trading Halt Ahead of Key Announcement
PremiumCompany Announcements
Avecho Biotechnology Sees Revenue Surge Amidst Continued R&D Investments
PremiumCompany Announcements
Avecho Biotechnology Addresses ASX Price Query Amid Milestone Speculation
PremiumCompany Announcements
Avecho Biotechnology Advances CBD Trial and Strengthens Manufacturing Ties
PremiumCompany Announcements
Avecho Biotechnology Updates on Director Interests---
AVE FAQ
What was Avecho Biotechnology Limited’s price range in the past 12 months?
Currently, no data Available
What is Avecho Biotechnology Limited’s market cap?
Avecho Biotechnology Limited’s market cap is AU$12.68M.
When is Avecho Biotechnology Limited’s upcoming earnings report date?
Avecho Biotechnology Limited’s upcoming earnings report date is Sep 01, 2025 which is in 144 days.
How were Avecho Biotechnology Limited’s earnings last quarter?
Avecho Biotechnology Limited released its earnings results on Feb 27, 2025. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Avecho Biotechnology Limited overvalued?
According to Wall Street analysts Avecho Biotechnology Limited’s price is currently Overvalued.
Does Avecho Biotechnology Limited pay dividends?
Avecho Biotechnology Limited does not currently pay dividends.
What is Avecho Biotechnology Limited’s EPS estimate?
Avecho Biotechnology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avecho Biotechnology Limited have?
Avecho Biotechnology Limited has 3,169,297,000 shares outstanding.
What happened to Avecho Biotechnology Limited’s price movement after its last earnings report?
Avecho Biotechnology Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Avecho Biotechnology Limited?
Currently, no hedge funds are holding shares in AU:AVE
---
Avecho Biotechnology Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AVE Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-64.72%
Trailing 12-Months
Asset Growth
-31.73%
Trailing 12-Months
Company Description
Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
---
Imugene Limited
―
PYC Therapeutics Limited
―
Neuroscientific Biopharmaceuticals Ltd.
―
Botanix Pharmaceuticals Limited
―
---